Literature DB >> 23322464

Factors influencing concordance between clinical and ultrasound findings in rheumatoid arthritis.

Marion Le Boedec1, Sandrine Jousse-Joulin, Jean-François Ferlet, Thierry Marhadour, Gérard Chales, Laurent Grange, Cécile Hacquard-Bouder, Damien Loeuille, Jérémie Sellam, Jean-David Albert, Jacques Bentin, Isabelle Chary-Valckenaere, Maria-Antonietta D'Agostino, Fabien Etchepare, Philippe Gaudin, Christophe Hudry, Maxime Dougados, Alain Saraux.   

Abstract

OBJECTIVE: Clinical joint examination (CJE) is less time-consuming than ultrasound (US) in rheumatoid arthritis (RA). Low concordance between CJE and US would indicate that the 2 tests provide different types of information. Knowledge of factors associated with CJE/US concordance would help to select patients and joints for US. Our objective was to identify factors associated with CJE/US concordance.
METHODS: Seventy-six patients with RA requiring tumor necrosis factor-α (TNF-α) antagonist therapy were included in a prospective, multicenter cohort. In each patient, 38 joints were evaluated. Synovitis was scored using CJE, B-mode US (B-US), and power Doppler US (PDUS). Joints whose kappa coefficient (κ) for agreement CJE/US was < 0.1 were considered discordant. Multivariate analysis was performed to identify factors independently associated with CJE/US concordance, defined as factors yielding p < 0.05 and OR > 2.
RESULTS: Concordance before TNF-α antagonist therapy varied across joints for CJE/US (κ = -0.08 to 0.51) and B-US/PDUS (κ = 0.30 to 0.67). CJE/US concordance was low at the metatarsophalangeal joints and shoulders (κ < 0.1). Before TNF-α antagonist therapy, a low 28-joint Disease Activity Score (DAS28) was associated with good CJE/B-US concordance, and no factors were associated with CJE/PDUS concordance. After TNF-α antagonist therapy, only the joint site was associated with CJE/B-US concordance; joint site and short disease duration were associated with CJE/PDUS concordance.
CONCLUSION: Concordance between CJE and US is poor overall. US adds information to CJE, most notably at the metatarsophalangeal joints and shoulders. Usefulness is decreased for B-US when DAS28 is low and for PDUS when disease duration is short.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322464     DOI: 10.3899/jrheum.120843

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Ultrasound imaging of the joint damage in the patient with long-standing Rheumatoid Arthritis.

Authors:  G G Kakavouli; C Siagkri; S Zivanovic
Journal:  Hippokratia       Date:  2015 Jul-Sep       Impact factor: 0.471

2.  [Agreement between ultrasound-detected inflammation and clinical signs in ankles and feet joints in patients with rheumatoid arthritis].

Authors:  X R Deng; X Y Sun; Z L Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

3.  The correlation of ultrasound-detected synovitis in an individual small joint with overall clinical disease activity in patients with rheumatoid arthritis.

Authors:  Xuerong Deng; Xiaoying Sun; Wenhui Xie; Yu Wang; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2022-07-18       Impact factor: 3.650

Review 4.  Assessing rheumatoid arthritis disease activity with ultrasound.

Authors:  Rafael Mendonça da Silva Chakr; José Alexandre Mendonça; Claiton Viegas Brenol; Ricardo Machado Xavier; João Carlos Tavares Brenol
Journal:  Clin Rheumatol       Date:  2013-05-23       Impact factor: 2.980

5.  Musculoskeletal Ultrasound in Early Rheumatoid Arthritis - Correlations with Disease Activity Score.

Authors:  C Mitran; A Barbulescu; F A Vreju; C Criveanu; A Rosu; P Ciurea
Journal:  Curr Health Sci J       Date:  2015-01-29

6.  A Longitudinal Study of the 28 Joints of Disease Activity Score by Ultrasonographical Examination in Rheumatoid Arthritis Patients.

Authors:  Rabab Hussin Ali; Osama Sayed Daifallah; Hanan Sayed M Abozaid; Esam Mohmad Abu Alfadl; Sahar Abdel-Rahman Elsayed
Journal:  J Med Ultrasound       Date:  2019-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.